MedTrace Logo

Anlotinib Retrospective Study for Esophageal Cancer

NCT05303740 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-03-31

No results posted yet for this study

Summary

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Conditions

  • Esophageal Neoplasms

Interventions

DRUG

Anlotinib

This is an observational study.

Sponsors & Collaborators

  • Feng Wang

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303740 on ClinicalTrials.gov